As of today (2024-04-16), Predictive Oncology's share price is $1.50. Predictive Oncology's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.98. Hence, Predictive Oncology's Price to Tangible Book Ratio of today is 0.76.
The historical rank and industry rank for Predictive Oncology's Price-to-Tangible-Book or its related term are showing as below:
POAI'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.73 Med: 2.42 Max: 15.49
Current: 0.76
During the past 13 years, Predictive Oncology's highest Price to Tangible Book Ratio was 15.49. The lowest was 0.73. And the median was 2.42.
POAI's Price-to-Tangible-Book is ranked better than 89.69% of 708
companies
in the Medical Devices & Instruments industry
Industry Median: 2.615
vs POAI: 0.76
A closely related ratio is called PB Ratio. As of today, Predictive Oncology's share price is $1.50. Predictive Oncology's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.04. Hence, Predictive Oncology's P/B Ratio of today is 0.74.
Predictive Oncology Price-to-Tangible-Book Historical Data
The historical data trend for Predictive Oncology's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Predictive Oncology Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
-
-
2.12
1.12
1.67
Predictive Oncology Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
1.12
1.42
1.35
1.13
1.67
Competitive Comparison
For the Medical Instruments & Supplies subindustry, Predictive Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology Price-to-Tangible-Book Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Predictive Oncology Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Predictive Oncology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Predictive Oncology (Predictive Oncology) Business Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your 